Showing results (61-70 of 111) with videos related to

Sort By:
Pageof 12
European Journal of Haematology|June 5, 2020
Characteristics and potential biomarkers of adult sickle cell patients with chronic painCamila Albo, Sanjiv Kumar, Michael Pope, et al.
Blood|May 4, 2011
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell miceSteffen E Meiler, Marlene Wade, Ferdane Kutlar, et al.
Experimental Hematology|November 10, 2018
MIR-144-mediated NRF2 gene silencing inhibits fetal hemoglobin expression in sickle cell diseaseBiaoru Li, Xingguo Zhu, Christina M Ward, et al.
American Journal of Hematology|February 10, 2022
Pregnancy outcomes with hydroxyurea use in women with sickle cell diseaseBarbara L Kroner, Jane S Hankins, Norma Pugh, et al.
Therapeutic Advances in Hematology|November 5, 2024
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults studyJulie Kanter, Sarah Mennito, Santosh M Nair, et al.
American Journal of Hematology|June 1, 2010
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-upMartin H Steinberg, William F McCarthy, Oswaldo Castro, et al.
Blood Advances|November 10, 2022
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell diseaseJulie Kanter, R Clark Brown, Cynthia Norris, et al.
Neurobiology of Aging|December 13, 2006
Hemoglobin binding to A beta and HBG2 SNP association suggest a role in Alzheimer's diseaseRodney T Perry, Debra A Gearhart, Howard W Wiener, et al.
British Journal of Haematology|February 18, 2011
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)Kenneth I Ataga, Marvin Reid, Samir K Ballas, et al.
Haematologica|October 4, 2017
Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with Index of Hydroxyurea ResponsivenessXingguo Zhu, Tianxiang Hu, Meng Hsuan Ho, et al.
Pageof 12